Belite Bio, Inc
Status: Publicly traded
Direct answer
Belite Bio, Inc is publicly traded on NASDAQ under the ticker BLTE.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is...
Can you invest in Belite Bio, Inc?
Yes. Belite Bio, Inc trades publicly on NASDAQ as BLTE.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Belite Bio, Inc
Detailed equity research is provided by MarketSnap.